Literature DB >> 26812077

Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface.

Melissa Samo1, Neelima R Choudhary2, Kristina J Riebe1, Ivo Shterev1, Herman F Staats3, Gregory D Sempowski4, Isabelle Leduc5.   

Abstract

The Ducreyi serum resistance A (DsrA) protein of Haemophilus ducreyi belongs to a large family of multifunctional outer membrane proteins termed trimeric autotransporter adhesins responsible for resistance to the bactericidal activity of human complement (serum resistance), agglutination and adhesion. The ability of DsrA to confer serum resistance and bind extracellular matrix proteins lies in its N-terminal passenger domain. We have previously reported that immunization with a recombinant form of the passenger domain of DsrA, rNT-DsrA, in complete/incomplete Freund's adjuvant, protects against a homologous challenge in swine. We present herein the results of an immunogenicity study in mice aimed at investigating the persistence, type of immune response, and the effect of immunization route and adjuvants on surrogates of protection. Our results indicate that a 20 μg dose of rNT-DsrA administered with alum elicited antisera with comparable bacterial surface reactivity to that obtained with complete/incomplete Freund's adjuvant. At that dose, high titers and bacterial surface reactivity persisted for 211 days after the first immunization. Administration of rNT-DsrA with CpG or imiquimod as adjuvants elicited a humoral response with similar quantity and quality of antibodies (Abs) as seen with Freund's adjuvant. Furthermore, intramuscular administration of rNT-DsrA elicited high-titer Abs with significantly higher reactivity to the bacterial surface than those obtained with subcutaneous immunization. All rNT-DsrA/adjuvant combinations tested, save CpG, elicited a Th2-type response. Taken together, these findings show that a 20 μg dose of rNT-DsrA administered with the adjuvants alum, CpG or imiquimod elicits high-quality Abs with reactivity to the bacterial surface that could protect against an H. ducreyi infection.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DsrA; Haemophilus ducreyi; Trimeric autotransporter adhesin; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 26812077      PMCID: PMC6278816          DOI: 10.1016/j.vaccine.2016.01.024

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  45 in total

1.  Haemophilus ducreyi associates with phagocytes, collagen, and fibrin and remains extracellular throughout infection of human volunteers.

Authors:  M E Bauer; M P Goheen; C A Townsend; S M Spinola
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Passive immunization with a polyclonal antiserum to the hemoglobin receptor of Haemophilus ducreyi confers protection against a homologous challenge in the experimental swine model of chancroid.

Authors:  Isabelle Leduc; William G Fusco; Neelima Choudhary; Patty A Routh; Deborah M Cholon; Marcia M Hobbs; Glen W Almond; Paul E Orndorff; Christopher Elkins
Journal:  Infect Immun       Date:  2011-06-06       Impact factor: 3.441

3.  Immunization with the Haemophilus ducreyi hemoglobin receptor HgbA with adjuvant monophosphoryl lipid A protects swine from a homologous but not a heterologous challenge.

Authors:  William G Fusco; Galyna Afonina; Igor Nepluev; Deborah M Cholon; Neelima Choudhary; Patricia A Routh; Glenn W Almond; Paul E Orndorff; Herman Staats; Marcia M Hobbs; Isabelle Leduc; Christopher Elkins
Journal:  Infect Immun       Date:  2010-06-28       Impact factor: 3.441

4.  Chronic cutaneous ulcers secondary to Haemophilus ducreyi infection.

Authors:  Trisha N Peel; Deepak Bhatti; Jim C De Boer; Ivan Stratov; Denis W Spelman
Journal:  Med J Aust       Date:  2010-03-15       Impact factor: 7.738

5.  Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.

Authors:  Dianna Rynkiewicz; Melinda Rathkopf; Iain Sim; A Thomas Waytes; Robert J Hopkins; Lallan Giri; Deborah DeMuria; Janet Ransom; James Quinn; Gary S Nabors; Carl J Nielsen
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

6.  The Haemophilus ducreyi serum resistance antigen DsrA confers attachment to human keratinocytes.

Authors:  Leah E Cole; Thomas H Kawula; Kristen L Toffer; Christopher Elkins
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

7.  Localization of the domains of the Haemophilus ducreyi trimeric autotransporter DsrA involved in serum resistance and binding to the extracellular matrix proteins fibronectin and vitronectin.

Authors:  Isabelle Leduc; Bonnie Olsen; Christopher Elkins
Journal:  Infect Immun       Date:  2008-11-17       Impact factor: 3.441

Review 8.  Vaccine adjuvants: putting innate immunity to work.

Authors:  Robert L Coffman; Alan Sher; Robert A Seder
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

9.  Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).

Authors:  Jacob T Minang; Jon R Inglefield; Andrea M Harris; Janet L Lathey; David G Alleva; Diane L Sweeney; Robert J Hopkins; Michael J Lacy; Edward W Bernton
Journal:  Vaccine       Date:  2014-02-13       Impact factor: 3.641

10.  Mass treatment with single-dose azithromycin for yaws.

Authors:  Oriol Mitjà; Wendy Houinei; Penias Moses; August Kapa; Raymond Paru; Russell Hays; Sheila Lukehart; Charmie Godornes; Sibauk Vivaldo Bieb; Tim Grice; Peter Siba; David Mabey; Sergi Sanz; Pedro L Alonso; Kingsley Asiedu; Quique Bassat
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

View more
  7 in total

1.  Meningococcal Detoxified Outer Membrane Vesicle Vaccines Enhance Gonococcal Clearance in a Murine Infection Model.

Authors:  Kathryn A Matthias; Kristie L Connolly; Afrin A Begum; Ann E Jerse; Andrew N Macintyre; Gregory D Sempowski; Margaret C Bash
Journal:  J Infect Dis       Date:  2022-02-15       Impact factor: 7.759

2.  The Outer Membrane Proteins and Their Synergy Triggered the Protective Effects against Pathogenic Escherichia coli.

Authors:  Guihong Pen; Na Yang; Da Teng; Ya Hao; Ruoyu Mao; Jianhua Wang
Journal:  Microorganisms       Date:  2022-05-08

3.  Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.

Authors:  Michael A Collier; Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Monica M Johnson; Andrew N Macintyre; Gregory D Sempowski; Eric M Bachelder; Jenny P-Y Ting; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2018-10-15       Impact factor: 4.939

4.  The BtaF Adhesin Is Necessary for Full Virulence During Respiratory Infection by Brucella suis and Is a Novel Immunogen for Nasal Vaccination Against Brucella Infection.

Authors:  Florencia Muñoz González; Gabriela Sycz; Iván M Alonso Paiva; Dirk Linke; Angeles Zorreguieta; Pablo C Baldi; Mariana C Ferrero
Journal:  Front Immunol       Date:  2019-07-26       Impact factor: 7.561

5.  The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.

Authors:  Isabelle Leduc; Kristie L Connolly; Afrin Begum; Knashka Underwood; Stephen Darnell; William M Shafer; Jacqueline T Balthazar; Andrew N Macintyre; Gregory D Sempowski; Joseph A Duncan; Marguerite B Little; Nazia Rahman; Eric C Garges; Ann E Jerse
Journal:  PLoS Pathog       Date:  2020-12-08       Impact factor: 6.823

Review 6.  Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets.

Authors:  Arno Thibau; Alexander A Dichter; Diana J Vaca; Dirk Linke; Adrian Goldman; Volkhard A J Kempf
Journal:  Med Microbiol Immunol       Date:  2019-12-01       Impact factor: 3.402

Review 7.  Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials.

Authors:  Jill Whitley; Christopher Zwolinski; Christian Denis; Maureen Maughan; Leonie Hayles; David Clarke; Meghan Snare; Hong Liao; Sean Chiou; Tina Marmura; Holly Zoeller; Ben Hudson; John Peart; Monica Johnson; Amelia Karlsson; Yunfei Wang; Cynthia Nagle; Cherell Harris; Daniel Tonkin; Stephanie Fraser; Lieza Capiz; Christina L Zeno; Yvonne Meli; Diana Martik; Daniel A Ozaki; Amy Caparoni; Jason E Dickens; Drew Weissman; Kevin O Saunders; Barton F Haynes; Gregory D Sempowski; Thomas N Denny; Matthew R Johnson
Journal:  Transl Res       Date:  2021-12-04       Impact factor: 7.012

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.